• Vaccines

Ervebo Generic Name & Formulations

General Description

Ebola Zaire vaccine, live recombinant (contains a minimum of 72million plaque forming units of vaccine virus in a stabilizer solution containing 10mM tromethamine and 2.5mg/mL rice-derived recombinant human serum albumin); per 1mL; susp for IM inj; may contain trace amounts of rice protein; preservative-, and latex-free.

Pharmacological Class

Ebola Zaire vaccine.

How Supplied

Single-dose vials—10


Generic Availability


Ervebo Indications


Prevention of disease due to Zaire ebolavirus.

Limitations of Use

The duration of protection conferred by Ervebo is unknown. Does not protect against other species of Ebolavirus or Marburgvirus. Effectiveness of the vaccine when administered concurrently with antiviral medication, immuneglobulin, and/or blood or plasma transfusions is unknown.

Ervebo Dosage and Administration


Give by IM inj, preferably in deltoid region of the non-dominant arm. ≥18yrs: administer one (1mL) dose.


<18yrs: not established.

Ervebo Contraindications


Allergy to rice protein.

Ervebo Boxed Warnings

Not Applicable

Ervebo Warnings/Precautions


Immunization may not protect all individuals. Have appropriate medical treatment and supervision available to manage allergic reactions. Immunocompromised. Possible transmission of vaccine virus. Pregnancy. Nursing mothers.

Ervebo Pharmacokinetics

See Literature

Ervebo Interactions


May test (+) results for anti-Ebola glycoprotein (GP) antibody and/or Ebola GP nucleic acid or antigens.

Ervebo Adverse Reactions

Adverse Reactions

Inj site reactions (pain, swelling, redness), headache, feverishness, muscle pain, fatigue, joint pain, nausea, arthritis, rash, abnormal sweating.

Ervebo Clinical Trials

See Literature

Ervebo Note

Not Applicable

Ervebo Patient Counseling

See Literature